iFAST Diagnostics Raises £5M to Speed Same-Shift Tests

iFAST Diagnostics posted trial data on 31 August 2026 showing its rapid antimicrobial susceptibility test matched the lab gold standard in three NHS hospitals. The Hampshire company had already raised £5 million in May to put that same-shift result into more UK labs.

The product claim is results in under 3 hours from a Gram-negative positive blood culture or from bacterial isolates. That speed is meant to cut the stretch when doctors treat sepsis with a broad drug because the lab has not yet said which one works.

Empiric Cover Still Runs Ahead of the Lab

Surviving Sepsis guidance, cited in the new trial paper, tells hospitals to start empiric antibiotics within 1 hour of presentation. Conventional AST, including broth microdilution and disk diffusion, typically needs 24 to 48 hours after a blood culture turns positive, so the first drugs a septic patient receives are a guess.

Tim Irish, general partner at Meridian Health Ventures, put the whole current process at more than 40 hours when he backed the May round. About 20 to 30 percent of patients with bloodstream infections get an inadequate first regimen, while many more stay on a wide-spectrum drug they never needed. Both mistakes feed resistance.

THE HUMAN COST OF SLOW AST

• Direct deaths, 2021: The GRAM Project counted 1.14 million deaths caused by bacterial antimicrobial resistance that year.
• Associated deaths: A broader 4.71 million deaths involved resistant bacteria as a contributing factor.
• 2050 forecast: Direct AMR deaths rise to 1.91 million a year on current trends, with 8.22 million associated deaths.
• Cumulative toll: The same team estimated more than 39 million deaths by 2050 caused directly by resistant infections.

Dr Mohsen Naghavi, who leads AMR research at the Institute for Health Metrics and Evaluation, said antimicrobial medicines are one of the cornerstones of modern healthcare, and rising resistance to them is a major cause for concern. The JCM authors separately cite nearly 49 million sepsis cases and 11 million deaths a year. A faster phenotypic result does not invent a new drug. It tells a clinician whether the drug already on the trolley will work before the next shift ends.

A Three-Centre Trial Cleared the 95 Percent Bar

The paper, published on 31 August 2026, is titled “Multisite clinical evaluation of the iFAST rapid antimicrobial susceptibility test direct from positive blood cultures containing gram-negative organisms.” It reports the first clinical study of the iFAST ONE system in three centres under ISO 20776-2:2021.

Teams at Queen Alexandra Hospital in Portsmouth, Southampton General Hospital, and the pKpD laboratory at Southmead Hospital in Bristol tested 375 Gram-negative samples across 7 species. The comparator was broth microdilution on custom Sensititre plates, read with EUCAST breakpoints from table v. 15 (2025). The trial panel held 15 antimicrobials used for bloodstream infection, from ampicillin and gentamicin through meropenem, ceftazidime-avibactam and ciprofloxacin.

iFAST ONE VERSUS BROTH MICRODILUTION

Those figures sit above the 95 percent sensitivity and specificity bar the standard sets. Reproducibility, run with 12 isolates across the 3 sites in triplicate on 3 days with different operators, came in at 95.7 percent. The paper reported 97.8 percent agreement for Enterobacterales against the reference method.

These findings support the implementation of iFAST for same-shift AST results.

Journal of Clinical Microbiology, 31 August 2026

The Institute of Biomedical Science later gave iFAST its Best Use of Research award for the same validation work. Other rapid platforms already on the market, the authors noted, report phenotypic results in roughly 4 to 8 hours, among them VITEK REVEAL and Accelerate Pheno. iFAST is selling a cheaper, same-shift read, not the first rapid box in existence.

SYNLAB Signed as the First Commercial Lab Partner

UKCA marking arrived in February 2026 for testing patient samples direct from Gram-negative blood cultures. Clinicians in Great Britain can now use those results to pick an antibiotic. The company later added certification for Gram-negative isolates and for quantitative AST on meropenem and piperacillin-tazobactam, two workhorse hospital drugs.

SYNLAB UK and Ireland became the first commercial laboratory partner in the UK on 11 May 2026. Southwest Pathology Services in Taunton had started a lab evaluation on 2 February 2026. Under the expanded deal, that research work continues while the iFAST ONE system goes into routine clinical use. The pathology group said it would also build the evidence NHS buyers need for wider adoption.

The UK Health Security Agency placed the first multi-system commercial order, three instruments for its Countermeasure Development Evaluation and Preparedness Division labs, where scientists test new antimicrobials. The iFAST ONE system is UKCA certified for Gram-negative blood cultures, and ISO 13485 now covers design, manufacture and distribution. A Gram-positive panel is still in the future tense on the company’s own materials.

Toby King, the chief executive, said hospitals using the system will get AST results in under 3 hours instead of 24 to 48 hours, without raising the overall cost of testing. That is the sales pitch the May cheque was written to carry into more pathology networks, not into another year of bench science.

How the Chip Reads Bacteria in 30 Seconds

iFAST is a 2022 spin-out from the University of Southampton. Professor Hywel Morgan, deputy director of the Institute for Life Sciences, is chief technology officer. Dr Dan Spencer, who developed the method with Morgan, is vice president of engineering. Professor Mark Sutton chairs the advisory board. The instrument sits in Whiteley, Hampshire, at 1500 Parkway on Solent Business Park.

The assay is phenotypic. It does not look for a resistance gene and then infer a drug list. It watches what antibiotics do to live cells, which is why a missing gene does not get called susceptible by default.

THE iFAST ONE WORKFLOW

• Sample in: Bacteria from a positive blood bottle, or from isolated colonies, are suspended and exposed to a panel of antibiotics.
• Two-hour wait: The plate incubates for 2 hours, long enough for susceptible cells to change shape and membrane behaviour.
• Chip read: The reader pushes each well through a microfluidic impedance chip and measures about 5,000 individual bacteria, 30 seconds per well.
• Call out: Software compares exposed cells with an unexposed control and reports susceptible or resistant, plus a minimum inhibitory concentration, using EUCAST or CLSI rules.

The company prices the test from £30 per sample and says each reader handles up to 10 tests a day. Vacuum-dried 96-well panels store at room temperature with a 2-year shelf life. Hands-on time is short because the measurement itself is electrical, not a camera watching colonies grow overnight. The iFAST site calls this a $4 billion AST market. The bet is that labs will swap a 48-hour habit for a box that fits one shift and does not blow the consumables budget.

Meridian Paid Almost Five Times the Last Round

iFAST Diagnostics Limited closed a £5 million funding round in May 2026, an over-subscribed equity raise the company also prints as $6.7 million. Meridian Health Ventures led. QantX, RAW Ventures, OKG Capital and members of Cambridge Capital Group came back in. Innovate UK added a £2.1 million non-dilutive loan on top of the equity. The company said the round values it at almost five times the previous funding 18 months earlier and brings total investment to £12 million.

EQUITY AND GRANTS TO DATE

The three equity rounds add to £12 million. The Innovate UK loan sits beside that total, not inside it. Meridian, formerly KHP Ventures, is an NHS-anchored healthtech fund; Irish has sat with the company since the earlier cheques. King founded the firm in 2022 and took the first outside money in 2023.

This investment is hugely significant as it allows us to continue our go-to-market strategy at pace, only three years after founding the company.

Dr Toby King, CEO, iFAST Diagnostics

Irish said AMR is one of the defining public health challenges of our generation, and iFAST is taking that challenge head-on with a cost-effective solution already being placed in UK hospital laboratories. The use of proceeds is not a new chip. It is UK expansion, an EU file, and a faster clinical and regulatory programme for the FDA.

The Money Now Has to Buy Approvals Abroad

A certified box in Hampshire is not a changed drug chart in Manchester. On 18 May 2026, nine days before the round was public, King spoke at a Microbiology Society session on taking a diagnostic through approval, access, procurement and adoption. That agenda is the real invoice. Pathology networks still run overnight AST. Stewardship teams still have to act on a result that lands at 4 p.m. A reader that handles 10 tests a day will not empty a 40-hour backlog unless someone writes it into the method book and the tender.

WHAT WE KNOW

• UK mark: UKCA is in force for Gram-negative blood cultures and for Gram-negative isolates, with quantitative claims on meropenem and piperacillin-tazobactam.
• Accuracy file: The 31 August 2026 JCM study is public and exceeds ISO 20776-2:2021 acceptance criteria on the 375-sample set.
• Paying users: SYNLAB is on a commercial contract and UKHSA has ordered 3 systems.

WHAT IS UNCONFIRMED

• EU timing: The company will seek EU approval with the new capital; no decision date is on the table.
• FDA file: A US clinical and regulatory programme is funded, not filed in public as complete.
• Gram-positive panel: The company still describes that panel as follow-on work, not a live UKCA claim.

The next customers have to believe a £30 well is cheaper than two extra days of meropenem, and that a same-shift MIC is worth rewriting the night-shift SOP. Irish’s “already being placed” line is true in a small number of rooms. It is not yet true of British microbiology as a whole.

The paper is out, the UKCA mark is in force, and SYNLAB is paying. The £5 million is for the labs that have not moved their 48-hour habit, and for the EU and FDA queues that still sit in front of a $4 billion market.

Disclaimer: This article is news reporting and analysis of a company financing round, a published clinical evaluation and related regulatory steps. It is informational only and is not medical advice, a diagnostic recommendation, or guidance on which antibiotic or laboratory test a patient or hospital should use. Readers who are making treatment, laboratory or procurement decisions should consult a qualified clinician, clinical microbiologist or regulatory professional who can apply local protocols and current breakpoints. Figures, certificates and commercial statuses reflect the company statements, the 31 August 2026 Journal of Clinical Microbiology paper and the GRAM Project estimates cited here, and those items can change as further data, filings or contracts appear.